ArticleWorld journal of surgical oncology2026
Predictors of postoperative morbidity and delayed initiation of adjuvant chemotherapy after cytoreductive surgery in advanced-stage epithelial ovarian cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to identify the factors predicting postoperative morbidity after cytoreductive surgery in patients with advanced-stage epithelial ovarian cancer, to evaluate the effect of this morbidity on the time to initiation of adjuvant chemotherapy, and to examine the association between delayed chemotherapy and survival outcomes.
methodsPatients with FIGO stage III-IV epithelial ovarian cancer who underwent surgery at a tertiary university hospital between May 2020 and December 2024 were retrospectively evaluated. Severe postoperative complications were defined as Clavien-Dindo grade IIIa or higher. Initiation of adjuvant chemotherapy later than 42 days after surgery was considered delayed. Clinical, laboratory, and perioperative variables associated with postoperative complications were analyzed using univariable and multivariable logistic regression analyses. Survival analyses were performed separately in the primary debulking surgery (PDS) and interval debulking surgery (IDS) groups.
resultsA total of 180 patients were included in the study, and 20 (11.1%) developed postoperative complications. In comparative analyses, bowel surgery (OR 3.55, 95% CI 1.32-9.34, p = .010), perioperative transfusion (OR 5.28, 95% CI 1.84-19.05, p = .004), and postoperative transfusion (OR 3.17, 95% CI 1.20-9.34, p = .025), were found to be significantly more frequent in the group that developed complications. In multivariable analysis, only perioperative transfusion was identified as an independent risk factor for postoperative complications (OR: 3.72; 95% CI: 1.17-14.25; p = .035). No significant association was found between the time to initiation of adjuvant chemotherapy and most patient- and surgery-related variables; however, chemotherapy was initiated earlier in patients who underwent IDS. In survival analyses, no significant association was observed between the timing of chemotherapy initiation and progression-free survival or overall survival in the PDS group, whereas in patients undergoing IDS, early initiation of chemotherapy was associated with significantly improved overall survival (p = .0013).
conclusionIn advanced-stage epithelial ovarian cancer, morbidity after cytoreductive surgery appears to be more closely related to surgery-related factors. Timely initiation of adjuvant chemotherapy may be particularly important for overall survival, especially in patients undergoing IDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.